ARS Pharmaceuticals (SPRY) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
ARS Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 4 sold $1.9M of SPRY stock on the open market.
Get emailed when insiders cluster-buy stocks like SPRY
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
SPRY insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | $284K | 2 |
| Q1 2026 | — | 0 | — | 0 |
| Q4 2025 | — | 0 | $1.7M | 3 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 ARS Pharmaceuticals, Inc. insiders reported open-market purchases totaling $0, while 4 insiders reported sales totaling $1.9M. 2 of 5 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jun 12SEC | Eric KarasChief Commercial Officer | Sell Plan | 25,00012,176 held (−67%) | $10.00 | $250K | -57.7% | — |
| Jun 12SEC | Alexander A FitzpatrickGeneral Counsel | Sell Plan | 3,35590,910 held (−4%) | $10.00 | $34K | -57.7% | — |
| Nov 14SEC | Justin ChakmaChief Business Officer | Sell | 136,380 | $8.86 | $1.2M | -52.3% | — |
| Nov 14SEC | Justin ChakmaChief Business Officer | Sell | 30,000136,380 held (−18%) | $8.91 | $267K | -52.5% | — |
| Nov 14SEC | Brian DorseyCOO | Sell | 21,82810,789 held (−67%) | $8.71 | $190K | -51.4% | — |
Insiders at ARS Pharmaceuticals, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Justin ChakmaChief Business Officer | — | $1.5M | Nov 14, 2025 | — |
| Eric KarasChief Commercial Officer | — | $250K | Jun 12, 2026 | — |
| Brian DorseyCOO | — | $190K | Nov 14, 2025 | — |
| Alexander A FitzpatrickGeneral Counsel | — | $34K | Jun 12, 2026 | — |
SPRY stock: common questions
Are ARS Pharmaceuticals, Inc. insiders buying SPRY stock?
In the past 12 months, 0 insiders reported open-market purchases of SPRY worth $0.
Are ARS Pharmaceuticals, Inc. insiders selling SPRY stock?
4 insiders reported sales worth $1.9M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is SPRY's 52-week range?
Over the past year SPRY has traded between $4.07 and $13.06. It last closed at $4.23 on Oct 9, 2026.